Contineum Therapeutics, Inc. cotiza a 8.56 USD y tiene una capitalización bursátil de $322M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophos…
| Periodo | 2026-10 | 2026-07 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.40 | $-0.39 | $-0.49 |
| Estimado | $-0.45 | $-0.45 | $-0.53 | $-0.39 |
| Sorpresa | — | +11.1% | +26.4% | -25.6% |
| Métrica | CTNM | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -23.0% | -40.4% | +17.4% |
| ROA | -21.7% | -32.0% | +10.3% |
| Current Ratio | 27.50 | 2.84 | +24.66 |
| Debt / Equity | — | 0.28 | — |